FAQ

losoxantrone

Known as: 7-hydroxy-2(2-((2-hydroxyethyl) amino) ethyl)5-(2-((2-hydroxyethyl)amino)ethyl)amino anthra(1,9-cd)pyrazole-6(2H)-one 
An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2006
012319942006

Related topics

Related topics

8 relations

Broader (3)

AnthraquinonesAntineoplastic AgentsPyrazolones

Narrower (3)

BiantrazoleCI 941DuP 941
NSC 357885anthrapyrazolone

Related mentions per year

Related mentions per year

1943-2018
19401960198020002020
losoxantrone
Antineoplastic Agents
Anthraquinones
Pyrazolones
anthrapyrazolone
CI 941

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
A Structure-Based 3D-QSAR Study of Anthrapyrazole Analogues of the Anticancer Agents Losoxantrone and Piroxantrone
A series of 13 anthrapyrazole compounds that are analogues of piroxantrone and losoxantrone were synthesized, and their cell… (More)
Is this relevant?
2002
2002
The oxidative biotransformation of losoxantrone (CI-941).
The oxidative biotransformation of the anticancer drug 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino… (More)
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2002
2002
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours
Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines. The recommended single agent… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • table 3
Is this relevant?
2001
2001
Elimination pathways of [14C]losoxantrone in four cancer patients.
Losoxantrone is an anthrapyrazole derivative in Phase III development in the U.S. for solid tumors, notably breast cancer. To… (More)
Is this relevant?
2001
2001
A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts.
OBJECTIVES Systematic investigation of a novel series of intercalating agents, 9-aza-anthrapyrazoles, has led to the… (More)
Is this relevant?
2000
2000
A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Our purpose in this study was to determine the efficacy and toxicity of losoxantrone (DuP-941), an anthrapyrazole, in patients… (More)
  • table 2
  • table 1
  • table 3
Is this relevant?
1999
1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
A Phase I and pharmacological study was performed to evaluate the feasibility, maximum tolerated dose (MTD), dose-limiting… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1999
1999
Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone.
Lucanthone is an antitumour drug used as an adjuvant in radiation therapy. The drug intercalates into DNA and inhibits… (More)
Is this relevant?
1996
1996
Validation of cleaning procedures for highly potent drugs. I. Losoxantrone.
The validation of a procedure designed to clean glass and stainless steel surfaces after exposure to the experimental anticancer… (More)
Is this relevant?
1994
1994
Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
BACKGROUND The cumulative cardiotoxicity of anthracyclines is thought to result from the generation of free radicals. New DNA… (More)
Is this relevant?